The Nordic Life Science Days is the largest partnering conference for life sciences in the Nordic countries. Inven2 will participate with a joint...
Licensing validates Norwegian platform technology for the development of tailored monoclonal antibodies
This summer, the U.S.-based biotechnology company Mage Biologics Inc (“Mage Bio”) was formed as a collaboration between the Swiss specialty pharma...
The platform company Authera, spun out of research at the University of Oslo and Oslo University Hospital, reports that they have entered into a...
Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.
Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.
Key figures 2010 – 2022
# Ideas evaulated (DOFI)
# Companies established
# Licence agreements
# New patent applications
MNOK transferred back to research, innovation and inventors
# Clinical Trials managed